Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (referred to as Mbody AI Ltd. in metadata) covers the period ending June 2, 2017. The registrant is a foreign private issuer based in Israel. The filing primarily reports the closing of a registered direct offering and a concurrent private placement of securities.
Key Financial Metrics and Capital Structure
The filing details a capital raise transaction rather than operational financial performance. Key metrics include:
- Shares Issued: 1,349,500 ordinary shares.
- Purchase Price: $2.00 per share.
- Gross Proceeds: Approximately $2.699 million (calculated as 1,349,500 shares x $2.00).
- Warrants Issued: 1,349,500 warrants to investors at an exercise price of $2.125 per share, immediately exercisable.
- Placement Agent Warrants: 67,475 warrants issued to Rodman & Renshaw (Wainwright) at an exercise price of $2.50 per share.
- Transaction Costs: 7% of gross proceeds paid as fees to the placement agent, plus $60,000 for non-accountable expenses.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, existing debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in share capital and the issuance of new warrants resulting from the June 2, 2017 closing. This transaction dilutes existing shareholders and increases the company's cash position by the net proceeds of the offering. No prior comparable period data is provided in this specific filing to assess operational changes.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the securities issuance. The transaction was executed pursuant to a Securities Purchase Agreement dated May 30, 2017. The filing incorporates by reference into Post-Effective Amendment No. 1 to Form S-8 and Form F-3 Registration Statements.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7% placement fee and $60,000 expense reimbursement.
- Confirm the total number of outstanding shares and warrants post-transaction to assess dilution impact.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or redemption rights.
- Check the press release (Exhibit 99.1) for the stated intended use of proceeds.
- Confirm the exercise terms and expiration dates of the investor warrants versus the Wainwright warrants.